Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2025-12-26 @ 4:06 PM
Study NCT ID:
NCT01931033
Status:
COMPLETED
Last Update Posted:
2024-07-01
First Post:
2013-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
Sponsor:
Massachusetts General Hospital
Organization:
Study Overview
Official Title:
An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectrum disorders in adolescents ages 11-17.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: